

GLAXOSMITHKLINE PLC

Form 6-K

February 19, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 19 February 2019

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms E Walmsley
  - b) Position/status Chief Executive Officer
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

Ordinary shares of 25 pence each ('Ordinary Shares')

  - a) Description of the financial instrument ISIN: GB0009252882
  - b) Nature of the transaction Transfer of 102,035 Ordinary Shares between accounts for nil consideration.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£0.00	102,035
  - d) Aggregated information Aggregated volume Price n/a (single transaction)
  - e) Date of the transaction 2019-02-18
  - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms E Walmsley
  - b) Position/status Chief Executive Officer
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence  
each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction Transfer of 102,035 Ordinary  
Shares to spouse for nil  
consideration.

No change in beneficial  
ownership.

c) Price(s) and volume(s)  
Price(s) Volume(s)  
£0.00 102,035

Aggregated information n/a (single transaction)

d) Aggregated volume  
Price

e) Date of the transaction 2019-02-18

f) Place of the transaction n/a

Details of PDMR/person closely associated with them ('PCA')

a) Name Mr David Owen  
b) Position/status PCA of Ms E Walmsley  
(Chief Executive Officer)  
c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type  
of instrument; (ii) each type of transaction; (iii) each date; and (iv)  
each place where transaction(s) has been conducted

Ordinary shares of 25 pence  
each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction Receipt of 102,035 Ordinary  
Shares from spouse for nil  
consideration.

c) Price(s) and volume(s)  
Price(s) Volume(s)  
£0.00 102,035

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Aggregated information	n/a (single transaction)
d) Aggregated volume	
Price	
e) Date of the transaction	2019-02-18
f) Place of the transaction	n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 19, 2019

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc